186 related articles for article (PubMed ID: 33110616)
1. Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
Hersh CM; Harris H; Ayers M; Conway D
Mult Scler J Exp Transl Clin; 2020; 6(4):2055217320959815. PubMed ID: 33110616
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
4. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.
Vollmer B; Nair KV; Sillau SH; Corboy J; Vollmer T; Alvarez E
Mult Scler J Exp Transl Clin; 2017; 3(3):2055217317725102. PubMed ID: 28839949
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.
Vollmer B; Ontaneda D; Bandyopadhyay A; Cohn S; Nair K; Sillau S; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
Neurol Clin Pract; 2018 Aug; 8(4):292-301. PubMed ID: 30140580
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair KV; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2019 Feb; 6(2):252-262. PubMed ID: 30847358
[TBL] [Abstract][Full Text] [Related]
8. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
[TBL] [Abstract][Full Text] [Related]
9. A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod.
Salter A; Lancia S; Cutter G; Marrie RA; Mendoza JP; Lewin JB; Fox Mellen RJ
Ther Adv Neurol Disord; 2021; 14():17562864211021177. PubMed ID: 34262613
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.
Hersh CM; Altincatal A; Belviso N; Kapadia S; de Moor C; Rudick R; Williams JR; Miller C; Koulinska I
Mult Scler J Exp Transl Clin; 2022; 8(1):20552173211069852. PubMed ID: 35024161
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.
Hersh CM; Love TE; Bandyopadhyay A; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler J Exp Transl Clin; 2017; 3(3):2055217317715485. PubMed ID: 28890796
[TBL] [Abstract][Full Text] [Related]
12. Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study.
Diem L; Daponte A; Findling O; Miclea A; Briner M; Salmen A; Gold R; Kilidireas C; Chan A; Evangelopoulos ME; Hoepner R
Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31937596
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
[TBL] [Abstract][Full Text] [Related]
14. Persistence to oral disease-modifying therapies in multiple sclerosis patients.
Lattanzi S; Danni M; Taffi R; Cerqua R; Carlini G; Pulcini A; Provinciali L; Silvestrini M
J Neurol; 2017 Nov; 264(11):2325-2329. PubMed ID: 28831550
[TBL] [Abstract][Full Text] [Related]
15. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
[TBL] [Abstract][Full Text] [Related]
16. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
17. The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis.
Reynolds A; Gaughan M; Holden D; Redenbaugh V; Dunne J; Redmond J; Conlon N
Ir J Med Sci; 2022 Dec; 191(6):2759-2762. PubMed ID: 35028898
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
[TBL] [Abstract][Full Text] [Related]
19. First-ever treatment in multiple sclerosis.
Pantazou V; Pot C; Du Pasquier R; Le Goff G; Théaudin M
Rev Neurol (Paris); 2021; 177(1-2):93-99. PubMed ID: 32771209
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
